Verici Dx
plc
("Verici Dx" or the
"Company")
Successful completion of
Thermo Fisher Scientific licensing and commercialisation
agreement
Formal launch of
Pre-Transplant Risk Assessment Assay using Verici's prognostic
testing technology
Verici Dx plc (AIM: VRCI), a
developer of advanced clinical diagnostics for organ
transplant, notes that Thermo Fisher Scientific, the world
leader in serving science, has announced the formal launch of its
One Lambda™ Pre-Transplant Risk Assessment ("PTRA") Assay via its
CLIA facility in Fishers, Indiana, utilizing the pre-transplant
prognostic testing technology licensed by the Company to Thermo
Fisher Scientific under the terms of a global licensing and
commercialisation agreement announced on 15 November 2023 (the
"Agreement").1
Commenting on the milestones, Sara Barrington, CEO of Verici
Dx, said:
"I am delighted to see that the PTRA
Assay is being launched to the clinical community so swiftly and
look forward to seeing how it can help transform patient outcomes.
Together with the successful transfer of technology, this
demonstrates our Company's commitment to timely and effective
collaboration when executing these types of
agreements."
Tina
Liedtky, President, Transplant Diagnostics, Thermo Fisher
Scientific said:
"We're excited to introduce this
innovative new tool that may
help clinicians make more informed
decisions about post-transplant management
by providing
information about patient risk of early acute
rejection based on a patient's unique gene profile prior to
transplant."
Enquiries:
|
Verici Dx
|
www.vericidx.com
|
|
|
Sara Barrington, CEO
|
investors@vericidx.com
|
|
|
Julian Baines, Chairman
|
|
|
|
|
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser &
Broker)
|
Tel: +44 20 7496
3000
|
|
|
Phil Davies / Sam Butcher
|
|
|
|
|
|
Notes
1.
Please refer to RNS number 4652T for further
information. A copy of this announcement can also be found on the
company website https://verici-dx-plc.flint-platform.com/regulatory-news/62760
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a
complementary suite of leading-edge tests forming a kidney
transplant platform for personalised patient and organ response
risk to assist clinicians in medical management for improved
patient outcomes. The underlying technology is based upon
artificial intelligence assisted transcriptomic analysis to provide
RNA signatures focused upon the immune response and other
biological pathway signals critical for transplant prognosis of
risk of injury, rejection and graft failure from pre-transplant to
late stage. The Company also has a mission to accelerate the pace
of innovation by research using the fully characterised data from
the underlying technology, including through collaboration with
medical device, biopharmaceutical and data science
partners.
The foundational research was driven
by a deep understanding of cell-mediated immunity and is enabled by
access to expertly curated collaborative studies in highly
informative cohorts in kidney transplant.